Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MCARH125 |
| Trade Name | |
| Synonyms | MCARH-125|MCARH 125 |
| Drug Descriptions |
MCARH125 are autologous T-cells engineered to express a chimeric antigen receptor (CAR) that targets the B-cell maturation antigen (BCMA; TNFRSF17), which potentially induce cytotoxicity in tumor cells expressing BCMA (NCI Drug Dictionary). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C188226 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| MCARH109 + MCARH125 | MCARH109 MCARH125 | 0 | 1 |
| MCARH125 | MCARH125 | 0 | 0 |